TVARDI THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
TVARDI THERAPEUTICS, INC. (TVRD) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $82.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2025-05-13
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $5.00M, a 86.43% decline year-over-year.
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $2.50M, a 94.60% decline year-over-year.
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-06-30 was $15.50M, a 63.76% decline year-over-year.
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-03-31 was $59.00M, a 100.00% increase year-over-year.
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $82.00M, a 47.25% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $155.44M, a 29.48% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $220.44M, a 27.06% increase from fiscal 2021.
- TVARDI THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $173.48M, a 20.21% increase from fiscal 2020.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $7.50M derived: sum of 2 quarters · filed 2025-03-11 | $23.00M derived: sum of 3 quarters · filed 2025-03-11 | $82.00M 10-K · filed 2025-03-11 |
| 2024-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $18.00M derived: sum of 2 quarters · filed 2024-11-14 | $77.00M 10-Q · filed 2024-11-14 | $113.85M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $15.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $74.50M 10-Q · filed 2024-08-14 | $111.35M derived: sum of 3 quarters · filed 2025-05-13 | $157.68M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $59.00M 10-Q · filed 2025-05-13 | $95.85M derived: sum of 2 quarters · filed 2025-05-13 | $142.18M derived: sum of 3 quarters · filed 2025-05-13 | $184.94M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $36.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $83.18M derived: sum of 2 quarters · filed 2025-03-11 | $125.94M derived: sum of 3 quarters · filed 2025-03-11 | $155.44M 10-K · filed 2025-03-11 |
| 2023-09-30 | $46.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $89.09M derived: sum of 2 quarters · filed 2024-11-14 | $118.59M 10-Q · filed 2024-11-14 | $176.84M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $42.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $72.27M 10-Q · filed 2024-08-14 | $130.51M derived: sum of 3 quarters · filed 2025-03-11 | $198.45M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $29.50M 10-Q · filed 2024-05-13 | $87.75M derived: sum of 2 quarters · filed 2025-03-11 | $155.69M derived: sum of 3 quarters · filed 2025-03-11 | $205.94M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $58.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $126.19M derived: sum of 2 quarters · filed 2025-03-11 | $176.44M derived: sum of 3 quarters · filed 2025-03-11 | $220.44M 10-K · filed 2025-03-11 |
| 2022-09-30 | $67.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $118.19M derived: sum of 2 quarters · filed 2023-11-13 | $162.19M 10-Q · filed 2023-11-13 | $201.45M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $50.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $94.25M 10-Q · filed 2023-08-07 | $133.51M derived: sum of 3 quarters · filed 2024-03-06 | $187.26M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $44.00M 10-Q · filed 2023-05-15 | $83.26M derived: sum of 2 quarters · filed 2024-03-06 | $137.01M derived: sum of 3 quarters · filed 2024-03-06 | $189.83M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $39.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $93.01M derived: sum of 2 quarters · filed 2024-03-06 | $145.83M derived: sum of 3 quarters · filed 2024-03-06 | $173.48M 10-K · filed 2024-03-06 |
| 2021-09-30 | $53.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $106.56M derived: sum of 2 quarters · filed 2022-11-07 | $134.22M 10-Q · filed 2022-11-07 | $158.65M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $52.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $80.47M 10-Q · filed 2022-08-08 | $104.89M derived: sum of 3 quarters · filed 2023-03-06 | $127.14M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $27.66M 10-Q · filed 2022-05-09 | $52.08M derived: sum of 2 quarters · filed 2023-03-06 | $74.33M derived: sum of 3 quarters · filed 2023-03-06 | $116.50M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $24.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $46.67M derived: sum of 2 quarters · filed 2023-03-06 | $88.84M derived: sum of 3 quarters · filed 2023-03-06 | $144.32M 10-K · filed 2023-03-06 |
| 2020-09-30 | $22.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $64.42M derived: sum of 2 quarters · filed 2021-11-08 | $119.89M 10-Q · filed 2021-11-08 | $177.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $42.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $97.64M 10-Q · filed 2021-08-09 | $155.39M derived: sum of 3 quarters · filed 2022-03-01 | $228.35M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $55.48M 10-Q · filed 2021-05-10 | $113.22M derived: sum of 2 quarters · filed 2022-03-01 | $186.18M derived: sum of 3 quarters · filed 2022-03-01 | $229.76M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $57.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $130.70M derived: sum of 2 quarters · filed 2022-03-01 | $174.29M derived: sum of 3 quarters · filed 2022-03-01 | $253.58M 10-K · filed 2022-03-01 |
| 2019-09-30 | $72.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $116.54M derived: sum of 2 quarters · filed 2020-11-09 | $195.84M 10-Q · filed 2020-11-09 | $285.64M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $43.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $122.88M 10-Q · filed 2020-08-10 | $212.68M derived: sum of 3 quarters · filed 2021-02-25 | $241.48M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $79.30M 10-Q · filed 2020-05-11 | $169.09M derived: sum of 2 quarters · filed 2021-02-25 | $197.90M derived: sum of 3 quarters · filed 2021-02-25 | $227.94M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $89.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $118.60M derived: sum of 2 quarters · filed 2021-02-25 | $148.65M derived: sum of 3 quarters · filed 2021-02-25 | $175.30M 10-K · filed 2021-02-25 |
| 2018-09-30 | $28.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $58.85M derived: sum of 2 quarters · filed 2019-11-05 | $85.50M 10-Q · filed 2019-11-05 | $102.25M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $30.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $56.70M 10-Q · filed 2019-08-07 | $73.45M derived: sum of 3 quarters · filed 2020-02-27 | $102.95M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $26.65M 10-Q · filed 2019-05-07 | $43.40M derived: sum of 2 quarters · filed 2020-02-27 | $72.90M derived: sum of 3 quarters · filed 2020-02-27 | $92.65M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $16.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $46.25M derived: sum of 2 quarters · filed 2020-02-27 | $66.00M derived: sum of 3 quarters · filed 2020-02-27 | $82.16M 10-K · filed 2020-02-27 |
| 2017-09-30 | $29.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $49.25M derived: sum of 2 quarters · filed 2018-11-06 | $65.41M 10-Q · filed 2018-11-06 | $86.14M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $19.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $35.91M 10-Q · filed 2018-08-07 | $56.64M derived: sum of 3 quarters · filed 2019-03-12 | $73.89M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $16.16M 10-Q · filed 2018-05-09 | $36.89M derived: sum of 2 quarters · filed 2019-03-12 | $54.14M derived: sum of 3 quarters · filed 2019-03-12 | $70.49M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $20.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $37.98M derived: sum of 2 quarters · filed 2019-03-12 | $54.33M derived: sum of 3 quarters · filed 2019-03-12 | $80.38M 10-K · filed 2019-03-12 |
| 2016-09-30 | $17.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $33.60M derived: sum of 2 quarters · filed 2017-11-02 | $59.65M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $16.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $42.40M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $26.05M 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |